D-0559-2023 Class II Terminated
FDA drug recall D-0559-2023 was initiated by PD-Rx Pharmaceuticals, Inc. on Apr 6, 2023 and is designated Class II. Reason for recall: CGMP deviations. The recall status is terminated (terminated Apr 30, 2024). Affected quantity: 186 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- May 10, 2023
- Initiation Date
- Apr 6, 2023
- Termination Date
- Apr 30, 2024
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 186 bottles
Product description
Glimepiride USP, 4 mg, 90 count-bottles, Rx only, Intas Pharm. Limited Pkg By: PD-Rx Pharmaceuticals Incorporated Oklahoma City, OK 73127, NDC 43063-0587-90
Reason for recall
CGMP deviations.
Distribution pattern
Nationwide in the US.
Code information
Lots: A22B45 Exp. 01/31/24; C22A73, E22E41, C22D28, F22B68, G22A29, H22B97, K22A36 Exp. 03/31/24; K22B99, A23D07, B23B25 Exp. 10/31/24; B23B55 Exp. 06/30/25
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0559-2023
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026